Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 5/20 | 0.71 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.51 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.51 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 14/20 | 0.43 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL336901 | 0.94 | EGLN1 (0.73) | EGLN1FTOKDM5BKDM2AHIF1A | |
| SCHEMBL336903 | 0.89 | EGLN1 (0.79) | EGLN1FTOHIF1A | |
| SCHEMBL335835 | 0.84 | EGLN1 (0.81) | EGLN1HIF1A | |
| SCHEMBL336916 | 0.83 | EGLN1 (1.00) | EGLN1HIF1A | |
| SCHEMBL336659 | 0.83 | EGLN1 (0.70) | EGLN1HIF1A | |
| SCHEMBL336893 | 0.82 | EGLN1 (0.77) | EGLN1HIF1A | |
| SCHEMBL337557 | 0.82 | EGLN1 (0.80) | EGLN1HIF1A | |
| SCHEMBL336513 | 0.81 | EGLN1 (0.68) | EGLN1HIF1AEGLN3 | |
| SCHEMBL2576889 | 0.80 | EGLN1 (0.59) | EGLN1HIF1A | |
| SCHEMBL338044 | 0.80 | EGLN1 (0.71) | EGLN1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097620-B2 | Diazaquinolones that inhibit prolyl hydroxylase activity | AMGEN INC. (US) | 2012-01-17 | — | — | US | claimed |
| EP-2155746-A2 | DIAZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY | Amgen, Inc (US) | 2010-02-24 | — | — | EP | claimed |
| US-20090099171-A1 | Diazaquinolones that inhibit prolyl hydroxylase activity | AMGEN INC. (US) | 2009-04-16 | — | — | US | claimed |
| WO-2008137084-A2 | DIAZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY | AMGEN INC. (US) | 2008-11-13 | — | — | WO | claimed |
| US-8097620-B2 | Diazaquinolones that inhibit prolyl hydroxylase activity | AMGEN INC. (US) | 2012-01-17 | — | — | US | disclosed |
| US-8097620-B2 | Diazaquinolones that inhibit prolyl hydroxylase activity | AMGEN INC. (US) | 2012-01-17 | — | — | US | disclosed |
| US-8097620-B2 | Diazaquinolones that inhibit prolyl hydroxylase activity | AMGEN INC. (US) | 2012-01-17 | — | — | US | disclosed |
| EP-2155746-A2 | DIAZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY | Amgen, Inc (US) | 2010-02-24 | — | — | EP | disclosed |
| US-20090099171-A1 | Diazaquinolones that inhibit prolyl hydroxylase activity | AMGEN INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090099171-A1 | Diazaquinolones that inhibit prolyl hydroxylase activity | AMGEN INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090099171-A1 | Diazaquinolones that inhibit prolyl hydroxylase activity | AMGEN INC. (US) | 2009-04-16 | — | — | US | disclosed |
| WO-2008137084-A2 | DIAZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY | AMGEN INC. (US) | 2008-11-13 | — | — | WO | disclosed |
| WO-2008137084-A2 | DIAZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY | AMGEN INC. (US) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099171-A1 | Diazaquinolones that inhibit prolyl hydroxylase activity | EGLN3, EGLN2, HIF1AN | EGLN1 4/4885FTO 1088/4885KDM5B 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.